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Dominant-negative STAT5B mutations cause
growth hormone insensitivity with short stature
and mild immune dysregulation
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Growth hormone (GH) insensitivity syndrome (GHIS) is a rare clinical condition in which
production of insulin-like growth factor 1 is blunted and, consequently, postnatal growth
impaired. Autosomal-recessive mutations in signal transducer and activator of transcription
(STAT5B), the key signal transducer for GH, cause severe GHIS with additional character-
istics of immune and, often fatal, pulmonary complications. Here we report dominant-
negative, inactivating STAT5B germline mutations in patients with growth failure, eczema, and
elevated IgE but without severe immune and pulmonary problems. These STAT5B missense
mutants are robustly tyrosine phosphorylated upon stimulation, but are unable to nuclear
localize, or fail to bind canonical STAT5B DNA response elements. Importantly, each variant
retains the ability to dimerize with wild-type STAT5B, disrupting the normal transcriptional
functions of wild-type STAT5B. We conclude that these STAT5B variants exert dominant-
negative effects through distinct pathomechanisms, manifesting in milder clinical GHIS with
general sparing of the immune system.
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Patients diagnosed with growth hormone insensitivity syn-drome (GHIS) share common clinical characteristics ofimpaired postnatal growth due to low or undetectable
serum IGF1 concentrations despite normal or elevated growth
hormone (GH) concentrations1–3. Autosomal-recessive (AR)
mutations of the GH receptor, GHR (“Laron syndrome”, MIM
262500) are the most prevalent molecular cause of GHIS,
although a few autosomal-dominant (AD) cases have also been
reported (MIM 604271)4–9. STAT5B deficiency (MIM 245590), a
rare cause of GHIS with immunodeficiency, is an AR disorder,
first described in a patient with severe short stature (height SDS
−7.5), who was T-lymphopenic10, 11 and succumbed to a pro-
gressive pulmonary disease12. STAT5B, typical of STAT proteins,
is composed of discrete protein modules including a 4-alpha helix
coiled-coiled domain (CCD), a DNA-binding domain (DBD), an
SH2 (src-homology 2) domain for docking to phosphorylated
tyrosines, and a C-terminal transcriptional activation domain
(TAD). All seven recessively inherited inactivating STAT5B
mutations characterized to date lack functional SH2 and down-
stream TAD domains, and often the entire protein is immuno-
logically undetectable13. One copy of wild-type (WT) STAT5B
allele appears to be sufficient for normality as heterozygous
relatives of affected patients are of normal height and without
immunological or pulmonary complications14. Since STAT5B
functions as a dimer when activated, it is conceivable that natural
heterozygous STAT5B variants exist which disrupt dimeric
functions. Recurrent somatic activating heterozygous missense
STAT5B mutations in the SH2 or TAD domains, for example,
were recently identified and reported to be causal of lympho-
mas15–17. Germline heterozygous STAT5B variants associated
with impaired human growth and/or immunity have yet to be
identified. Our previous functional evaluations of two rare het-
erozygous STAT5B missense variants identified in children with
idiopathic short stature had demonstrated that the variants were
unlikely to be the sole cause of growth failure18,19.
We now report the first germline heterozygous STAT5B var-
iants with dominant-negative effects, identified by targeted and
whole-exome sequencing (WES), in short-statured subjects from
three unrelated families. Neither the index patients nor affected
relatives suffer from severe immunological disturbances. The
three missense mutations retain the capability to become robustly
tyrosine phosphorylated upon GH stimulation and, subsequently,
to form dimers with themselves or with the STAT5B WT protein.
However, their capacity to act as a transcription factor is blunted
since nuclear import is abrogated in STAT5B with a mutation
mapping to the CCD domain (p.Gln177Pro) while STAT5B
proteins with DBD mutations fail to bind canonical STAT5B
DNA response elements (p.Gln474Arg, p.Ala478Val). Impor-
tantly, each mutant STAT5B protein interferes with the normal
functions of the WT isoform. Altogether, we demonstrate that
specific heterozygous STAT5B germline mutations exert
dominant-negative effects resulting in STAT5B deficiency clini-
cally characterized by significant postnatal growth impairment,
mild GH insensitivity, eczema, and elevated IgE.
Results
Patients and variant identification. The clinical profiles of male
index patients from families 1 and 2 were consistent with GHIS,
with postnatal growth failure, serum IGF1 concentrations close to
(Proband 1) or below the detection limit (Proband 2), whereas
basal and stimulated GH serum concentrations were normal
(Table 1). For Proband 1, low serum concentrations of acid-labile
subunit (IGFALS) corroborated the diagnosis of GHIS13; for
Proband 2, the lack of response to exogenous GH in an extended
stepwise IGF1 generation test (Supplementary Table 1) confirmed
a state of GHIS. Moreover, affected siblings (Fig. 1a; the mono-
zygotic twin in family 1 and a brother in family 2) presented with
comparable biochemistries and growth profiles (see “Detailed
patient reports” in Supplementary Note 1 and Supplementary
Table 2). Initial targeted sequencing of key genes along the
GH–IGF1 axis revealed a de novo heterozygous STAT5B variant
in the twin brothers of family 1 (c.530A > C, exon 5, p.Gln177Pro;
CCD, Fig. 1b) and a maternally inherited c.1433C > T variant
(exon 12, p.Ala478Val, DBD) in family 2. Subsequent WES
analysis, performed in both families, excluded additional patho-
genic variants (for criteria used in the WES analysis pipeline, see
Supplementary Note 1 and Supplementary Tables 3 and 4).
For Proband 3, family 3, the top candidate variant from WES
analysis was a heterozygous STAT5B c.1421A > G variant (exon
12, p.Gln474Arg; DBD). A novel heterozygous JAK2 variant
(c.2374C > T, p.Pro792Ser) was also identified but did not
segregate with the clinical phenotype of the family (Supplemen-
tary Note 1 and Supplementary Table 4). Proband 3 had familial
short stature accompanied by autoimmune thyroiditis, celiac
disease, and poor growth response to rhGH treatment (Table 1).
Interestingly, Proband 3 and her two siblings who had short
stature and carried the variant, but not the affected father, also
presented with microcephaly (Supplementary Note 1 and
Supplementary Table 2). Re-analysis of the exome data for
potential variants that might contribute to the microcephalic
phenotype, however, were unrevealing. Of note, probands from
families 1 and 2 were not microcephalic.
None of our patients presented with symptoms of severe
immune dysfunction normally associated with STAT5B defi-
ciency20, although the majority of carriers of the identified
STAT5B variants had eczema (Fig. 1a), Proband 3 had
autoimmune thyroiditis and celiac disease which were success-
fully controlled, and Proband 1 had childhood bronchial asthma.
Immunological evaluations performed for STAT5B variant
carriers in the three families were normal, with the exception of
elevated IgE concentrations in eight out of nine patients
(Supplementary Table 2 and Supplementary Data 1).
Detailed patient phenotype and genetic analyses reports, and
immunological profiles of the three families can be found in the
Supplementary Information. These are the only three families in
whom a dominant-negative STAT5B mutation has been identi-
fied. Over the past decade, our research groups have investigated
a total of 164 children with marked short stature and overlapping
phenotypes of GHIS accompanied by variable symptoms
suggestive of immune dysregulation or in whom initial GHR
sequencing did not reveal any pathogenic genomic aberration.
Mutated STAT5B proteins are phosphorylated and can
dimerize. Each of the three non-synonymous STAT5B variants is
private and not listed in the large-scale variant databases, with
amino acid substitutions predicted to be pathogenic (Supple-
mentary Table 5). To evaluate functional pathogenicity, N-
terminally tagged STAT5B p.Gln177Pro, p.Ala478Val, and p.
Gln474Arg variants were re-generated. Expression of each variant
and GH-induced Tyr-phosphorylation (pSTAT5) were shown to
be comparable to those of tagged WT STAT5B in reconstituted
HEK293(hGHR) systems (Fig. 2a, upper panels). Co-
immunoprecipitation (co-IP) experiments, furthermore, sup-
ported homo-dimerization capabilities for each variant, and,
mimicking a heterozygous state, ability to hetero-dimerize with
WT STAT5B (Fig. 2a, bottom panels). Interestingly, p.Gln177Pro
demonstrated reproducible and robust, GH-induced phosphor-
ylation which was markedly and time-dependently sustained
(Fig. 2b). This enhanced STAT5 phosphorylation was corrobo-
rated in primary dermal fibroblasts (Fig. 2c, d) stimulated with
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04521-0
2 NATURE COMMUNICATIONS |  (2018) 9:2105 | DOI: 10.1038/s41467-018-04521-0 |www.nature.com/naturecommunications
GH or interferon gamma (IFNγ). Enhanced phosphorylation
(Fig. 2d) was not due to changes in basal STAT5B or GHR
expression patterns which were similar to those in control
fibroblasts (Fig. 2c, e).
Nuclear import of activated STAT5B p.Gln177Pro is abro-
gated. We next asked whether all phosphorylated STAT5B spe-
cies could translocate to the nucleus, a necessary step for
transcriptional actions. Immunofluorescent staining and decon-
volution microscopy revealed that the tagged p.Gln177Pro var-
iant, despite robust GH-induced phosphorylation and in contrast
to WT and the other two STAT5B variants, failed to enter the
nucleus, remaining localized to the cytoplasm and accumulated at
the nuclear membrane (Fig. 3a). Strikingly, when co-expressed
with WT STAT5B, not only did the p.Gln177Pro variant remain
cytoplasmic upon GH stimulation, but co-localization of the
variant and WT STAT5B was detected only in the cytoplasm and
by the nuclear membrane (Fig. 3b, bottom panels). Our results
strongly suggest that the p.Gln177Pro variant was defective in
nuclear localization and, when dimerized with WT STAT5B,
prevented the WT from mobilizing into the nucleus. Conversely,
WT STAT5B could not facilitate the nuclear localization of
associated p.Gln177Pro, suggesting that motifs or regions within
each of the associated monomers may both be required for
appropriate nuclear import.
STAT5B p.Gln474Arg and p.Ala478Val are DNA-binding
defective. For the p.Gln474Arg and p.Ala478Val variants, loca-
ted within the DBD module, we evaluated whether DNA binding
might be impaired, employing standard gel-shift electrophoretic
mobility shift assay (EMSA) analysis. WT STAT5B readily bound
and gel-shifted the STAT5B-specific DNA probe (GHRE) only
under GH-stimulated conditions (Fig. 3c). However, neither of
the two variants could gel-shift the probe, clearly demonstrating
loss of DNA-binding functions. When Myc-tagged STAT5B
variants were co-expressed with WT FLAG-STAT5B, gel-shifting
was observed under GH-stimulated conditions (Fig. 3d), but this
was attributed to bound WT FLAG-STAT5B, as the complexes
were further shifted (supershifted) by anti-FLAG antibody and
not by anti-Myc antibody (Fig. 3d). These results were consistent
with the absence of p.Gln474Arg or p.Ala478Val peptides from
the GHRE probe/protein complexes, suggesting that the protein
Table 1 Clinical characteristics of autosomal-dominant STAT5B-deficient index patients and comparison to previously reported
autosomal-recessive STAT5B cases
Proband 1 [p.Gln177Pro] Proband 2 [p.Ala478Val] Proband 3 [p.Gln474Arg] Published AR cases
{n}
Sex Male Male Female f/m= 7/3 {10}
Age (years) 14.5 1.8 12.8a 1.9–18.0 {10}
Birth data
Gestational age (weeks) 36 39 39 Preterm: 6/8 {8}
Birth weight (g) [SDS] 2500 [−0.9] 3460 [0.1] 3317 [0.2] [−2.4 to 3.0]b {6}
Birth length (cm) [SDS] 45 [−1.7] nd 48 [−0.2] [−2.4 to 2.3]b {5}
Auxological features
Weight (kg) [SDS] 28.0 [−4.5] 9.5 [−2.3] 22.8 [−4.7] [−6.7 to −3.6] {4}
Height (cm) [SDS] 131.5 [−5.3] 76.8 [−2.9] 123.8 [−4.5] [−9.9 to −4.3] {10}
Target height (SDS) −0.74 −0.83 −1.01 −1.98 to −0.11 {8}
Head circumference (SDS) −0.53 −1.70 −3.73 −1.40, −2.86 {2}
Bone age (years) 9.6 nd 8.8 Delayed: 7/7 {7}
Puberty Delayed na Delayed Delayed: 6/7 {7}
Endocrine features
GH, basal (ng ml−1) 0.4 3.2 2.0 0.1–17.6 {10}
GH, stimulated (ng ml−1) 16.2 17.3 4.0 6.6–53.8 {7}
IGF1 (ngml−1) [SDS/reference range] 56 [76–499] <25 [51–303] 208 [−1.5] <normal: 10/10 {10}
IGFBP3 (mg l−1) [SDS/reference
range]
2.33c [−1.7] 1.29 [0.8–3.9] 3.80 [3.9–9.4] <normal: 10/10 {10}
IGFALS [reference range] 418 p mol l−1 c
[986–1678]
nd 13 mg l−1 [5.6–16.0] <normal: 6/6 {6}
Prolactin (mU l−1) [reference range] 291c [86–324] 553 [163–1039] 621d [<383] >normal: 6/7 {7}
Immunological and pulmonary phenotype
IgE (kU l−1) [reference range] 156/340e [<200/<114] 118 [<52] 127 [<629] >normal: 4/7 {5}
Hemorrhagic Varicella No No No 5/5 {5}
Chronic pulmonary disease Recurrent infections No No 8/10 {10}
Lung fibrosis nd nd No 6/7 {7}
Lymphocytic interstitial pneumonia
(LIP)
nd nd No 7/8 {8}f
Eczema/skin pathology Yes Yes No 8/8 {8}
Otherwise disturbed immunological
profiles
No No No 5/7 {7}
Autoimmune disease No No Thyroiditis; celiac disease 6/10 {10}f
nd not determined, na not applicable. Standard deviation scores (SDS) and reference ranges are shown in brackets with reference ranges in italics
a Patient on GH treatment for 3 months
b Six of eight patients born AGA (appropriate for gestational age)
c Determined at age 16.5 years during rhIGF treatment
d Measured at 15.3 years while on rhIGF1 for 4 months
e Measured at two occasions
f Diagnosis confirmed or suspected
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component in all shifted complexes was composed solely of
phosphorylated, homo-dimeric, WT STAT5B.
The failure of STAT5B variants p.Gln474Arg and p.Ala478Val
to bind GHRE parallels the inability to drive transcriptional
activities as demonstrated by STAT5B-mediated luciferase
reporter assays. Neither of the two variants by themselves could
drive expression of the luciferase reporter (Fig. 3e) and when co-
expressed with WT STAT5B, the transcriptional activities of WT
STAT5B were significantly blunted compared to WT STAT5B
alone. Altogether, the results provide strong evidence that these
DBD variants ablated STAT5B DNA-binding capabilities and
prevented associated WT STAT5B from binding DNA and
functioning as a transcription factor.
Discussion
To date, the clinical condition of STAT5B deficiency has been
described exclusively as an AR trait, with the majority of muta-
tions causing early protein termination (nonsense, frameshift
mutations) and total STAT5B deficiency. Only two homozygous
STAT5B missense mutations have been reported, both mapping
to the SH2 domain and affecting overall protein stability and/or
functions10,21 (Fig. 1b). Here we report the identification of three
novel germline STAT5B missense variants, with demonstrable
dominant-negative effects, associated with short stature and mild
GHIS in three unrelated families. The two loss-of-function
missense variants in the DBD module are four amino acids apart,
while p.Gln177Pro is located in the CCD module (Supplementary
Fig. 1a, b). Each of the variants interacted with WT STAT5B,
exerting dominant-negative effects that, ultimately, reduced
transcriptional activity.
The p.Gln177Pro substitution, located towards the C-terminal
end of the first α-helix in the CCD (Supplementary Fig. 1e),
ablated ability to nuclear localize despite robust expression and
GH-induced phosphorylation. The predicted disruption of α-helix
1 by the proline substitution, surprisingly, did not destabilize the
whole protein (unlike the STAT5B p.Ala630Pro10). However, the
functional integrity of the four α-helices that comprise the CCD
was likely disrupted, as the helix bundle was recently shown to act
in concert as an unconventional nuclear localization signal22. The
inability of phosphorylated p.Gln177Pro to translocate to the
nucleus, where resident nuclear phosphatases act on phosphory-
lated STAT proteins23,24, could explain the accumulation of
cytosolic, phosphorylated STAT5B species. Interestingly, impaired
nuclear dephosphorylation also has been reported for AD, gain-of-
function, STAT1 CCD mutants that are associated with chronic
mucocutaneous candidiasis (MIM 614162), but none were
reported as defective in nuclear localization23,25. CCD loss-of-
function missense mutations in STAT3 (ref. 26), STAT2 (ref. 27),
and STAT6 (ref. 28) have yet to be reported. Hence STAT5B p.
Gln177Pro is the first described STAT variant with a nuclear
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Fig. 1 Segregation of heterozygous STAT5B missense mutations in the families. a Individuals bearing de novo (family 1) or inherited (families 2 and 3)
heterozygous STAT5B mutations are indicated by half-filled symbols. Standard deviation score of last reported height [SDS], relative immunoglobulin E
[IgE] levels, and the occurrence of eczema are shown below the symbols. Index patients are marked by an arrow. Question marks indicate an unknown
genotype. n.d., no data available. b Schematic of the STAT5B protein (drawn to scale) with major functional domains (domains: ND, N-terminal; CCD,
coiled-coil; DBD, DNA-binding; L, linker; SH2, src-homology 2; TAD, transactivation), their boundaries, and tyrosine residue (Tyr699) whose
phosphorylation is necessary for STAT5B activation. Positions of previously reported homozygous amino acid substitutions are shown above the bar
(arrows: red, protein truncating variants; blue, missense); heterozygous missense mutations identified in this study are indicated below the bar (green
arrows)
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The normal phosphorylation and nuclear trafficking of our
dominant-negative STAT5B DBD mutants, p.Gln474Arg and p.
Ala478Val, is remarkably similar to characterized, dominant-
negative STAT3 DBD mutations29–31 associated with hyper-IgE
syndrome (MIM 147060)31,32. The affected STAT5B residues,
Gln474 and Ala478, are conserved among all members of the
STAT family (Supplementary Fig. 1a). Gln474 resides within, and
Ala478 close to, a sequence segment that occupies the major
grove of bound DNA in all previously investigated STAT
homologous sequences (STAT1 (ref. 33), STAT3 (ref. 34), STAT6
(ref. 35); Supplementary Fig. 1b–d). The STAT5B p.Gln474Arg, in
particular, would be predicted to directly interfere with DNA
response element recognition, possibly by disrupting direct
hydrophobic and polar contacts between glutamine and thymines
and phosphates on the DNA backbone34, as was suggested for the
analogous heterozygous STAT3 p.Gln469His and p.Gln469Arg
mutations (Supplementary Fig. 1c, d). Altogether, heterozygous
expressed missense mutations within the STAT DBD domains
can negatively impact normal dimeric STAT transcriptional
functions, resulting in clinical syndromes and disorders.
All three heterozygous loss-of-function STAT5B missense
variants lead to postnatal growth restriction for the index patients
(height ranged from −2.9 to −5.3 SDS). Growth impairment in
our patients is likely due to the consequence of diminished
IGF1 serum concentrations and, presumably, extrahepatic resis-
tance to GH, e.g. at the growth plate36. Intra- and interfamilial
variability of stature in the three families was comparable to that
normally seen in AR GHIS1. Strikingly, the growth deficit was in
the range of patients carrying dominant-negative GHR muta-
tions4–9 (Supplementary Fig. 2), although heights were above −2
SDS in 3 out of the 11 individuals carrying dominant STAT5B
mutations, one of whom, II-6 of family 3, is quite young and will
be closely monitored. Overall, however, the phenotypes of our
patients are clearly distinct from those of heterozygous relatives of
AR STAT5B-deficient patients who typically have heights within
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Fig. 2 GH-dependent STAT5B activation is retained by the missense variants. Whole-cell lysates from untreated or GH-stimulated (30min or as shown)
HEK293(hGHR) (a) or HEK293 (b) cells transfected with the indicated FLAG- (F) or Myc-tagged (M) STAT5B wild-type (WT) or variant plasmids (p.
Gln177Pro, Q177P; p.Ala478Val, A478V; p.Gln474R, Q474R) were subjected to immunoprecipitation (IP) and/or immunoblotting (WIB) using antibodies
as indicated (pSTAT5, phospho-Tyr-STAT5). Representative immunoblots of three experiments are shown. c–e Whole-cell lysates were prepared from
primary dermal fibroblasts derived from affected twins in Family 1 and control fibroblasts, after stimulation with GH or IFNγ and immunoblotted for
pSTAT5, total STAT5B, or β-actin as a loading control. Representative blot out of four independent experiments is shown. d Densitometric evaluation of
pSTAT5 determined in patients’ fibroblasts (fold change compared to untreated cells). pSTAT5 levels were normalized to total STAT5B and β-actin protein
amounts in each sample. Data are shown as mean ± S.E.M. of three independent experiments. e qPCR verification of STAT5B and GHR mRNA expression
determined in fibroblasts from the index patient, his brother, and control cells. Mean ± S.E.M. of at least three independent experiments is shown. Statistical
analysis was performed by one-way ANOVA followed by Tukey’s post hoc test, p-values relative to control are indicated (ns, not significant)
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In Family 3, the father (I-1) also carried a private heterozygous
JAK2 variant c.2374C > T (p.Pro792Ser), which was transmitted
to five of his six children, one of whom (II-4) did not carry the
STAT5B p.Gln474Arg mutation. The binding of JAK2 by the
homo-dimeric GHR, which, like all Type I cytokine receptor, lack
intrinsic kinase activities, is crucial for activating the GH-induced
GHR signaling cascades. Since II-4, age 7.9 years, was of normal
stature (height SDS of −1.1), consistent with his normal
IGF1 serum concentrations, we concluded that the JAK2 variant
itself is unlikely to contribute significantly to postnatal growth
retardation. With a sample size of only one, however, a potential
synergistic effect with the STAT5B p.Gln474Arg mutation cannot
be entirely ruled out. Subject II-4, furthermore, was non-
syndromic (healthy, no evidence of eczema, normal IgE con-
centrations [Supplementary note 1]), suggesting that the JAK2
variant, by itself, did not contribute to the other symptoms
observed in affected family members. To date, loss-of-function
JAK2 mutations have not been reported while somatic and
germline dominantly inherited gain-of-function JAK2 variants,
particularly the recurrent p.Val617Phe, are well established causes
of hematologic disorders (thrombocythemia-3, thrombocytope-
nia, polycythemia vera)37–39. In family 3, there was a lack of
symptoms indicative of similar hematologic abnormalities, sug-
gesting JAK2 p.Pro792Ser is not a dominant gain-of-function
mutation. Altogether, the heterozygous JAK2 p.Pro792Ser is
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Fig. 3 STAT5B missense variants are defective in nuclear translocation or DNA binding. a Representative immunofluorescence images of untreated or GH-
stimulated HEK293(hGHR) cells transfected with Myc-STAT5B wild type (WT) or Myc-STAT5B variant plasmids (as indicated, abbreviations as in Fig. 2)
and stained with α-Myc antibodies and Hoechst 33342 nuclear staining (scale bar, 10 µm). b Images of GH-stimulated or untreated HEK293(hGHR) cells
transiently transfected with Myc-STAT5B wild type (WT) and co-transfected with plasmids expressing WT (upper panel) or p.Gln177Pro STAT5B (Q177P,
bottom panel) followed by immunostaining (IF) with α-FLAG or α-Myc antibodies and Hoechst 33342 (scale bar, 10 µm). c, d Representative (three
independent experiments) electrophoretic mobility shift assays (EMSA) (c) or supershift EMSA (d) to demonstrate DNA-binding of STAT5B WT and/or
variant proteins as indicated. d Supershift EMSA of FLAG-WT co-transfected with indicated Myc-tagged WT or variants (V, vector only control; arrow,
shifted; arrowhead, supershifted complexes). e Luciferase reporter activity measured in HEK293(hGHR) cells co-transfected with equimolar amounts of
the indicated FLAG-tagged plasmids. Activities are presented as fold increase above unstimulated vector control, which was arbitrarily assigned a value of
1.0. Error bars represent mean ± S.D. of four independent experiments, each time in duplicates. *p < 0.05, **p < 0.01 relative to GH-stimulated WT, using
one-way ANOVA with post hoc Tukey test
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observed in family 3. It remains possible that the JAK2 variant is
poorly penetrant in II-4 or is a recessive variant.
Our patients lacked the severe immune deficiency and patho-
logical autoimmunity typically associated with total STAT5B
deficiency. The immune complications of STAT5B deficiency are
attributed to T-lymphopenia, most notably impairment in
numbers and functions of T-regulatory cells (Treg) that express
the transcription factor FOXP3, Treg+FOXP3+, which are critical
for maintenance of T-cell homeostasis11,40. Specifically, in
STAT5B deficiency, it has been noted that peripheral, naïve Treg
subsets were low, while dividing memory Treg subsets (CD45RO
+Ki67+) were abnormally elevated and had reduced suppressive
functionality, thus likely contributed to the autoimmune pheno-
types of STAT5B-deficient patients40,41. Immunological profiles
(B, NK, T-lymphocytes) of our present patients, in contrast, were
unremarkable, with T-lymphocytes and subsets (Treg, Treg
+FOXP3+, naïve, and memory cells), in particular, to be within
normal ranges (Supplementary Data 1).
An unexpected phenotypic feature in Family 3 was micro-
cephaly in Proband 3 and two of her affected siblings but not in
the carrier father. Whether the reduced head circumference was a
consequence of the AD STAT5B mutation or, more likely, caused
by additional genetic variants, remains unclear, but no obvious
recessive or dominant candidate variants were revealed from
available exome data. It is notable that the relatively normal head
circumferences, albeit below the mean, of patients from families 1
and 2 were comparable to those observed in patients with GHIS42
(Supplementary Fig. 3).
Additional major features frequently seen in AR STAT5B
deficiency such as hyperprolactinemia13 were detected in only a
few of our AD STAT5B subjects (mother and aunt of family 2;
Proband 3), and extrapulmonary autoimmune disease41 was
diagnosed only in Proband 3 (thyroiditis and celiac disease).
Interestingly, elevated IgE concentrations manifested in only four
of seven tested AR STAT5B-deficient patients12,20,41 whereas
eight of our nine AD STAT5B-deficient patients presented ele-
vated IgE concentrations with the high penetrance, suggesting
strong correlations between dominant actions of our STAT5B
mutant proteins and IgE production. Mild eczema was reported
for the majority of carriers of dominant-negative STAT5B
mutations. Altogether, the clinical manifestations (i.e. growth
impairment, elevated IgE, eczema) suggest variability in pene-
trance of the mutant genotypes and are consistent with the milder
phenotype of AD STAT5B loss-of-function mutations (Supple-
mentary Table 2 and Supplementary Fig. 2).
The prevalence of inactivating STAT5Bmutations, either AR or
AD, remains difficult to accurately determine from studies per-
formed to date. Previous screenings for mutations or copy-
number variants performed in short-statured patients (total n=
377), for example, did not reveal any pathogenic STAT5B var-
iants18,43–46, whereas in our present study (164 patients), three
dominant-negative STAT5B mutations were identified. Future
screenings of GHIS patients will validate whether the additional
features of eczema and elevated IgE may be indications of
potential inactivating AD STAT5B mutations. Intriguingly,
each of the described loss-of-function germline STAT5B
mutation is private, while reported somatic, heterozygous,
STAT5B gain-of-function mutations associated with large gran-
ular lymphocytic leukemia or distinct types of T- or NK- lym-
phomas are clustered, often with the same mutation found in
more than one individual15–17,47–49. The observation that
STAT5B mutations, both germline loss-of-function and somatic
gain-of-function, lead to clinical manifestations associated with
dysfunctional T-lymphocytes, support critical roles of STAT5B in
T-lymphocyte biology which cannot be compensated by the
closely related STAT5A.
Both the clinical presentation of the patients and functional
studies support residual normal STAT5B activities when in the
heterozygous state. Since STAT5B actions require dimerization,
we hypothesize that mutant and WT monomers captured in WT:
mutant heterodimers are functionally inactive and only the
remaining predicted 25% WT:WT homodimers are tran-
scriptionally competent. While 25% of dimeric WT STAT5B is
clearly not adequate for full GH responsiveness, cytokine sig-
naling appears to be less sensitive to diminished concentrations of
active STAT5B, thus explaining the absence of severe immuno-
logic or pulmonary problems in our patients. Interestingly, in
mouse models, severe growth restriction and immune deficiency
were observed only in the knock-out of both the Stat5b and
Stat5a genes, but expression of normal Stat5a/b as low as ~10%
significantly reduced the severity of immunodeficiencies50,51.
Finally, in our patients, the lack of severe immune problems and
presence of residual WT STAT5B suggested that recombinant
human GH or rhIGF1 therapy might be effective for normalizing
growth, possibly dependent on the type of mutation. Effectiveness
of either therapy or a combination of both treatments remains to
be fully evaluated.
In conclusion, we report the first germline dominant-negative
STAT5B mutations observed in patients who demonstrated
milder but significant postnatal growth impairment, mild GH
insensitivity, eczema, and elevated IgE. The STAT5B p.Gln177Pro
variant is the first naturally occurring STAT mutation with a
defect in nuclear localization, while the p.Gln474Arg and p.
Ala478Val variants are DNA-binding deficient. These novel
STAT5B mutations, acting through distinct pathophysiological
mechanisms, manifested as milder clinical GHIS with general
sparing of the immune system, thus broadening the clinical
spectrum of STAT5B deficiency and GHI syndrome.
Methods
Patient consent and regulatory compliance. Written informed consent to par-
ticipate in the study was obtained from all adult subjects and parents of minors.
The study protocol including skin biopsy sampling from control individuals was in
accordance with the principles of the Declaration of Helsinki and was approved by
the Ethical Review Committee of the University of Leipzig, the Institutional Reg-
ulatory Board of the Cincinnati Children’s Hospital Medical Center, and the
Institutional Regulatory Board of the UCL Great Ormond Street Hospital Institute
of Child Health, London.
WES and Sanger DNA Sequencing analyses. Genomic DNA extracted from
whole blood was used for Sanger dideoxy-sequencing and WES. All coding exons
of the genes indicated in the “Detailed patient reports” (Supplementary Note 1),
including STAT5B were PCR amplified and subjected to direct sequencing (ABI
PRISM 3100 and 310 Genetic Analyzers; Thermo Fisher Scientific, Waltham, MA).
Sequences were compared to public references (for accession numbers see Sup-
plementary Table 5). Primer sequences can be provided on request.
WES was performed on genomic DNA samples from individuals indicated in
Supplementary Note 1 (“Detailed Patient Reports”). One microgram of dsDNA
was sheared by sonication to an average size of 200 base pair (bp) on a Covaris S2
instrument. Library construction was performed in an automated fashion on an
IntegenX Apollo324. After nine cycles of PCR amplification using the Clonetech
Advantage II kit, 1 µg of genomic library was recovered for exome enrichment
using the NimbleGen EZ Exome V2 kit. Libraries were sequenced on an Illumina
HiSeq2500, generating approximately 30 million paired end reads 125 bases long
each. Reads were aligned to the human reference genome version 19 (GRCh37)
with the Burrows Wheeler Aligner52. Our analysis methods utilized the Broad
Institute’s Genome Analysis Toolkit (GATK) and followed the pipeline described
in DePristo et al.53 along with the modifications listed in the “Best Practices”
document on their website [http://www.broadinstitute.org/gatk/]. Stringent
filtering was applied for rare, non-synonymous variants that passed quality filters
and had a read depth of >10 reads. Further filtering was performed depending on
the inheritance mode of short stature and GHIS characteristics in each family,
specifically de novo dominant, homozygous recessive, compound heterozygous, or
X-linked form of inheritance in family 1; in family 2, a dominant mode of
inheritance from the mother’s side of the family, X-linked recessive inheritance,
homozygous autosomal recessive, or a compound heterozygous pattern as well as
dominant inheritance; and dominant inheritance in family 3. For dominant modes
of transmission, given the severity of the phenotype, we excluded all variants
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present in public databases including the 1000 Genomes [http://
www.1000genomes.org], Exome Aggregation Consortium [http://exac.
broadinstitute.org/], and an internal exome database (>750 individuals; Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH), for recessive inheritance
models (homozygous or compound heterozygous) we excluded all variants that
were present in these databases with a minor allele frequency above 0.005.
Laboratory evaluation. Endocrine and immunological evaluations were per-
formed employing approved standard techniques established at the University
Hospitals of Hradec Kralove (Czech Republic) and Leipzig (Germany) for family 1,
Great Ormond Street Hospital (family 2), and the Mayo Medical Laboratories
(Rochester, MN) and the Diagnostic Immunology Laboratory at Cincinnati Chil-
dren’s Hospital Medical Center (Cincinnati, OH) for family 3. Extended IGF1
generation tests were designed and performed to assess severity of GH resistance in
family 2. The test followed a 3-step regimen, in which patients self-administered
subcutaneous injections of rhGH at doses indicated in Supplementary Table 1, each
step for 2 weeks with 4 weeks washout in between steps. Serum IGF1 and IGFBP3
were measured at start and end of each step using standard methods.
Plasmids and site-specific mutagenesis. STAT5B WT cDNA plasmid constructs
(WT) with or without N-terminal FLAG-tag or Myc-tag (F-STAT5B and
M-STAT5B, respectively54) were used as templates for generating the missense
variants, p.Gln177Pro (c.530A > C), p.Gln474Arg (c.1421A > G), and p.Ala478Val
(c.1433C > T) by site-specific mutagenesis (QuikChange Site-Directed Mutagenesis
Kit; Stratagene, La Jolla, CA), following the manufacturer’s protocol. The resultant
cDNA constructs carrying the point mutations were verified by Sanger DNA
sequencing.
Cell culture and transfection. Primary dermal fibroblasts were established from
skin biopsies taken from STAT5B patients of family 1 (14.5 years) and healthy age/
sex matched controls undergoing elective orthopedic surgeries. Fibroblasts were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
fetal-bovine serum (FBS), 100 Uml−1 penicillin, and 100 µg ml−1 streptomycin.
Cells between passages 6 and 12 were seeded at a density of 100,000 cells ml−1,
grown to approximately 70% confluency before stimulation experiments. HEK293
cells (ATCC; LGC Standards, Wesel, Germany) and HEK293 stably transfected
with the human GH receptor gene [HEK293(hGHR), kindly provided by Dr.
Richard J. Ross (University of Sheffield, Sheffield, UK)]55 were cultured in DMEM
supplemented with 10% FBS. Primary cells and cell lines were tested for
mycoplasma contamination repeatedly. Cells were transiently transfected with
pcDNA3.1 vector or plasmids encoding N-terminally FLAG- or Myc-tagged WT or
variant STAT5B, using ExGene DNA (BIOMOL, Hamburg, Germany) or PolyJet
In Vitro DNA (SignaGen, Rockville, MD) transfection systems, following the
manufacturers’ instructions. Briefly, 100,000 cells were seeded in six-well plates and
cultured to 60–70% confluence before an ExGene or PolyJet/plasmid solution was
added to cells (DMEM+ 10% FBS). For stimulation experiments, cells were
washed and serum-starved (DMEM with 0.1% bovine serum albumin) for 24 h
prior to treatment with GH (100 ng ml−1) or IFN-γ (100 ng ml−1). Total cell
lysates were collected 30 min post-treatment unless otherwise indicated.
Western immunoblot and co-immunoprecipitation analysis. Transfected
HEK293(hGHR) cells were solubilized in lysis buffer (1 × phosphate-buffered sal-
ine (PBS), 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mgml−1
phenylmethylsulfonyl fluoride, 100 nM sodium orthovanadate, and protease inhi-
bitor mixture (cOmplete Mini-EDTA-free; Sigma, St. Louis, MO)), cell debris
removed by centrifugation, and final whole-cell lysates stored at −20°C. For
nuclear cellular extracts of transfected HEK293(hGHR) cells (six-well tissue culture
plates), cells were trypsinized (0.25% trypsin) for 1 min, neutralized with DMEM/
10% FBS, and cells collected in chilled Eppendorf tubes. Collected cells were
washed in cold PBS and resuspended in 500 µl cold nuclear extraction buffer
containing 1 mM sodium orthovanadate and protease inhibitor mixture. Nuclear
extraction buffer contains 200 ml Hypotonic Buffer (25 mM Tris-HCl, pH 7.4, 10
mM NaCl and 7 mM MgCl2), 1 mM EDTA, 1 mM EGTA, and 1 mM DTT. After
15 min incubation on ice, 25 µl of 10% Triton X-100 was added to lyse the cell
membrane (5 min) The mixture was centrifuged at 14,000 rpm, 4°C, for 2 min, and
the supernatant (cytosolic fraction) was stored at −80°C. The nuclear pellet was
further washed in cold nuclear extraction buffer and centrifuged at 14,000 rpm, 2
min, 4°C. The washed nuclear pellet was resuspended in cold nuclear extraction
buffer (with 1 mM sodium orthovanadate and protease inhibitor mixture) and
stored at −80°C in 20 µl aliquots. For immunoblot analysis, 10 μg nuclear extract,
20 μg cytosolic extract, or 30 μg of whole-cell lysates were separated on 7% SDS-
polyacrylamide gels, transferred to nitrocellulose membranes, and probed with
anti-STAT5B (sc-1656, 1:1000; Santa Cruz, Dallas, TX), anti-FLAG M2 (F3165,
1:1000; Sigma, St. Louis, MO), anti-phospho-STAT5 (#9351, 1:1000 or #9359,
1:500; Cell Signaling, Danvers, MA), anti-Myc (#2278, 1:500; Cell Signaling), or
anti-β-actin antibodies (A1978 or A5316, 1:5000; Sigma) as indicated. For
immunoprecipitation prior to immunoblot analysis, tagged STAT5B variants were
pulled down from 300 μg whole-cell lysate with anti-Myc sepharose beads (Cell
Signaling). Secondary horseradish peroxidase-conjugated anti-mouse IgG or anti-
rabbit IgG antibodies, appropriate SuperSignal substrates (Thermo Fisher Scien-
tific, Waltham, MA), and GE Healthcare’s Hyperfilm ECL (Madison, WI) were
used for chemiluminescence visualization. Uncropped captures of immunoblots are
provided in Supplementary Figs. 4 and 5.
Immunofluorescent microscopy. HEK293(hGHR) cells, 5 × 104 per well, were
seeded on poly-lysine-coated eight-well chamber slides (Thermo Fisher Scientific),
and transfected with a total of 0.5 μg plasmid DNA. For co-transfections, a 1:1 ratio
of plasmid DNA was employed. Following GH treatment (100 ng ml−1, 30 min),
cells were washed in cold PBS and fixed with cold methanol, 5 min at −20 °C. For
immunofluorescent staining, cells were blocked with 5% goat serum and exposed
overnight to primary mouse-anti-FLAG (1:500) and/or rabbit-anti-Myc (1:50)
antibodies prior to treatment with secondary goat-anti-mouse-FITC (1:500;
626511; Thermo Fisher Scientific, Carlsbad, CA) and/or goat anti-rabbit-A555
antibodies (1:500; #A-21428; Life Technologies) for 4 h. Hoechst 33342 (Thermo
Fisher Scientific) was added (15 min) and coverslips mounted with ProLong Gold
(Thermo Fisher Scientific). Fluorescent images were obtained using a wide field
deconvolution system (GE Healthcare) consisting of an inverted Nikon TE 200
Eclipse microscope, a Kodak CH350 CCD camera, and the Deltavision operating
system. Images were acquired using a ×60 objective in a 1024 × 1024 format and
deconvolved with nine iteration using SoftWoRx software (Applied Precision, GE
Healthcare).
Luciferase reporter assays. HEK293(hGHR) cells (six-well plates) were tran-
siently co-transfected21 as described above with 1.0 μg pGL2: 8xGHRE (growth
hormone response element) luciferase reporter plasmid and a total of 1.0 µg
STAT5B WT and/or mutant cDNA plasmids or empty vector (each 0.5 μg) as
indicated. Transfected cells were incubated overnight prior to an 8 h serum-free
media treatment. Cells were stimulated with GH (100 ng ml−1, 24 h) and cell
lysates were collected and assayed using Promega’s Luciferase Assay System
(Promega, Madison, WI). Luciferase activity was measured on a Veritas Lumin-
ometer (Promega).
Electrophoretic mobility shift assay. 5′-Cy5.5-tagged rat spi2.1 GHRE (growth
hormone response element; 5′-ACGCTTCTACTAATCCATGTTCTGAGAAA
TCATCCAGTCTGCCCA-3′) was employed as probe for EMSAs56,57. Briefly, 50
fmol of the duplex DNA probe were incubated with 2 μg (standard EMSA) or 3 μg
(supershift assays) nuclear extracts (see above) at room temperature for 20 min,
protected from light, prior to size fractionation on a native 5% acrylamide gel (in
standard tris-borate-EDTA buffer). Bands were visualized by scanning the gel on
Li-Cor Odyssey CLx (Li-Cor Biotechnology, Lincoln, NE). For supershift EMSA, 2
μg of anti-FLAG antibody or 3 μg of anti-Myc antibody were included in the
reaction mix and incubated at room temperature for an additional 10 min prior to
size fractionation of the DNA–protein–antibody complexes.
Quantitative reverse-transcriptase PCR amplification. Total RNA was isolated
using RNeasy plus Mini Kit (Qiagen, Hilden, Germany). A total of 100 ng of RNA
was reverse transcribed using SuperScript III reverse transcriptase and random
hexamer [p(dN)6] primers (Thermo Fisher Scientific). Steady-state mRNA
expression was measured by quantitative real-time PCR using the 2× qPCR
MasterMix Plus Low ROX (Eurogentec, Seraing, Belgium) with an ABI 7500
Sequence Detection System (Applied Biosystems, Darmstadt, Germany). Expres-
sion analysis for STAT5B was performed with TaqMan Gene Expression Assay
(Hs00273500_m1; Applied Biosystems) and for GHR using primer/probe combi-
nation as described by Friedberg et al. (F: 5′-TTGGAATATTTGGGCTAACAG
TGA-3′; R: 5′-CCTCCTCTAATTTTCCTTCCTTGAG-3′; P: 5′-AGGATTAA
AATGCTGATTCTGCCCCCAG-3′)58. Transcript levels were normalized to the
mean of two housekeeping genes using the following primer/probe combinations:
β-Actin (ACTB): F: 5′-CGACGCGGCTACAGCTT-3′, R: 5′-CCTTAATGTCACG
CACGATTT-3′, P: 5′-ACCACCACGGCCGAGCGG-3′; TATA-box-binding
protein (TBP): F: 5′-TTGTAAACTTGACCTAAAGACCATTGC-3′, R: 5′-TTCG
GTGGCTCTCTTATCCTCATG-3′, P: 5′-AACGCCGAATATAATCCCAAGCGG
TTG-3′.
Statistical analyses. Data were analyzed by one-way ANOVA with post hoc
Tukey test. Statistical analysis of the data was performed using GraphPad Prism
5 software (GraphPad Software, La Jolla, CA).
Data availability. The authors declare that all the data supporting the findings of
this study are included in the article (or the Supplementary material) and available
from the corresponding author (V.H.) upon reasonable request. Data of pathogenic
mutations reported within this study have been deposited in ClinVar with the
accession codes SCV000681436 (p.Gln177Pro), SCV000680478 (p.Gln474Arg),
and SCV000693651 (p.Ala478Val). WES data that support the findings are not
publicly available due to information that could compromise the research parti-
cipants privacy/consent.
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